<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高季刊</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff =202 30817021022&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_campaign=pubmed -2<description>心血管高季刊：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20230817021022&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_campaign=pubmed-2" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 8 月 17 日星期四 06:10:26 +0000</lastbuilddate><pubDate> Wed, 16 Aug 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>档案单细胞基因组学揭示 DCIS 进展过程中持续存在的亚克隆</title><link/>https://pubmed.ncbi.nlm.nih.gov/37586362/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230817021022&amp;v=2.17.9.post6+86293ac<description>导管原位癌 (DCIS) 是浸润性乳腺癌的常见前兆。我们对其基因组进展到复发性疾病的了解仍然很少，部分原因是与福尔马林固定石蜡包埋 (FFPE) 材料的基因组分析相关的挑战。,我们开发了 Arc-well，这是一种与 FFPE 材料兼容的高通量单细胞 DNA 测序方法。我们通过对来自细胞系、冷冻组织和 27 个细胞的 40,330 个单细胞进行分析来验证我们的方法。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 8 月 10 日：S0092-8674(23)00802-4.doi: 10.1016/j.cell.2023.07.024.打印前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">导管原位癌 (DCIS) 是浸润性乳腺癌的常见前兆。我们对其基因组进展到复发性疾病的了解仍然很少，部分原因是与福尔马林固定石蜡包埋 (FFPE) 材料的基因组分析相关的挑战。,我们开发了 Arc-well，一种与 FFPE 材料兼容的高通量单细胞 DNA 测序方法。我们通过分析来自细胞系、冷冻组织的 40,330 个单细胞以及来自乳腺、肺部分析的 27 个 FFPE 样本来验证我们的方法对 10 名患有相匹配的 DCIS 和 2-16 年后复发的癌症的患者进行的研究表明，许多原发性 DCIS 已经经历了全基因组加倍和克隆多样化，并且他们与持续进化分析共享基因组谱系，表明我们队列中的大多数 DCIS 病例都经历了全基因组加倍和克隆多样化。进化瓶颈，并进一步确定了与复发相关的持久亚克隆中的染色体畸变。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37586362/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817021022&v=2.17.9.post6+86293ac">37586362</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.07.024>10.1016/j.cell.2023.07.024</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37586362</guid><pubDate> Wed, 16 Aug 2023 06:00:00 -0400</pubDate><dc:creator>王凯乐</dc:creator><dc:creator>塔普西·库马尔更多</dc:creator><dc:creator>王俊科</dc:creator><dc:creator>达尔兰·孔特诺·米努西</dc:creator><dc:creator>诚惠美</dc:creator><dc:creator>李建卓</dc:creator><dc:creator>Tuan M Tran更多</dc:creator><dc:creator>阿蒂什·特纳万</dc:creator><dc:creator>胡敏</dc:creator><dc:creator>Anna K Casasent更多</dc:creator><dc:creator>肖珍娜</dc:creator><dc:creator>白珊珊</dc:creator><dc:creator>雷阳</dc:creator><dc:creator>洛林·M·金</dc:creator><dc:creator>Vandna Shah更多</dc:creator><dc:creator>佩特拉·克里斯特尔</dc:creator><dc:creator>卡罗琳·L·范德博登</dc:creator><dc:creator>杰弗里·R·马克斯</dc:creator><dc:creator>赵跃辉</dc:creator><dc:creator>阿马多·苏里塔</dc:creator><dc:creator>安娜·阿帕里西奥</dc:creator><dc:creator>布莱恩·查平 (Brian Chapin) 更多</dc:creator><dc:creator>杰业</dc:creator><dc:creator>张建军</dc:creator><dc:creator>唐·L·吉本斯</dc:creator><dc:creator>大挑战精密联盟</dc:creator><dc:creator>埃利诺·索耶</dc:creator><dc:creator>阿拉斯泰尔·M·汤普森</dc:creator><dc:creator>安德鲁·富特瑞尔</dc:creator><dc:creator>黄雪莱</dc:creator><dc:creator>耶勒·韦塞林</dc:creator><dc:creator>埃斯特·H·利普斯</dc:creator><dc:creator>尼古拉斯·E·纳文</dc:creator><dc:date>2023-08-16</dc:date><dc:source>细胞</dc:source><dc:title>档案单细胞基因组学揭示 DCIS 进展过程中持续存在的亚克隆</dc:title><dc:identifier>下午：37586362</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.07.024</dc:identifier></item><item><title>先进成像技术和生物标志物的未来研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/37587554/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230817021022&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 17 日：ehad530。doi：10.1093/eurheartj/ehad530。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37587554/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817021022&v=2.17.9.post6+86293ac">37587554</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad530>10.1093/eurheartj/ehad530</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37587554</guid><pubDate> Wed, 16 Aug 2023 06:00:00 -0400</pubDate><dc:creator>法布里奇奥·蒙特库科</dc:creator><dc:creator>托马斯·H·辛德勒</dc:creator><dc:date>2023-08-16</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>先进成像技术和生物标志物的未来研究</dc:title><dc:identifier>下午：37587554</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad530</dc:identifier></item><item><title>急性心肌梗塞中的炎症：好、坏和丑陋</title><link/>https://pubmed.ncbi.nlm.nih.gov/37587550/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230817021022&amp;v=2.17.9.post6+86293ac<description>综合实验和临床证据已经确定了促炎症途径在冠状动脉疾病中的病理生理学重要性。值得注意的是，治疗急性心肌梗死 (AMI) 患者炎症的兴趣现在正从慢性方面扩展到急性情况。已经通过针对残留炎症风险（RIR）（即阴燃风险）证明了抗炎治疗对心血管结局的益处。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 17 日：ehad486。doi：10.1093/eurheartj/ehad486。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">综合实验和临床证据已经确定了促炎途径在冠状动脉疾病中的病理生理学重要性。值得注意的是，治疗急性心肌梗死 (AMI) 患者炎症的兴趣现在正从慢性方面扩展到急性情况。已经证明抗炎治疗通过针对残余炎症风险（RIR）（即 AMI 后晚期持续存在的低度炎症的阴燃余烬）对心血管结局有益。AMI 后抗炎治疗的潜在风险，特别是与宿主防御相关的受损。最近，许多小规模试验提出了针对 AMI 后早期阶段过度炎症的有害爆发的概念。针对不同的途径并实施各种治疗方案，这些试验取得了不同程度的成功. 那些早期干预白细胞介素-1 和 -6 途径的研究取得了有希望的结果。从过去的研究中吸取经验教训可能会为针对 AMI 后炎症的优化方法提供信息，专门针对“好的”（修复和防御）进行定制同时治疗“坏的”（闷烧的 RIR）并捕获“丑陋的”（在急性期过度炎症的早期爆发）。这种策略的关键组成部分可以解读如下：选择具有大量促炎负担的患者（即大 AMI）；尽早开始治疗（例如 AMI 后≤12 小时）；实施精确靶向的抗炎药物；遵循逐渐减量的治疗方案。严格的临床试验。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37587550/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817021022&v=2.17.9.post6+86293ac">37587550</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad486>10.1093/eurheartj/ehad486</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37587550</guid><pubDate> Wed, 16 Aug 2023 06:00:00 -0400</pubDate><dc:creator>迈克尔·A·马特</dc:creator><dc:creator>弗朗西斯科帕内尼</dc:creator><dc:creator>——彼得·利比</dc:creator><dc:creator>斯特凡·弗朗茨</dc:creator><dc:creator>芭芭拉·E·斯塔利</dc:creator><dc:creator>克里斯蒂安·坦普林</dc:creator><dc:creator>亚历山德罗·门戈齐</dc:creator><dc:creator>王玉仁</dc:creator><dc:creator>托马斯·昆迪格</dc:creator><dc:creator>洛伦兹·拉贝尔</dc:creator><dc:creator>弗兰克·鲁斯奇卡</dc:creator><dc:creator>克里斯蒂安·马特</dc:creator><dc:date>2023-08-16</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>急性心肌梗塞中的炎症：好、坏和丑陋</dc:title><dc:identifier>下午：37587550</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad486</dc:identifier></item><item><title>在儿科人群中，罗斯手术相对于其他瓣膜替代术的优越性：这仅仅是开始！</title><link/> https://pubmed.ncbi.nlm.nih.gov/37587549/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230817021022&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 17 日：ehad461。doi：10.1093/eurheartj/ehad461。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37587549/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817021022&v=2.17.9.post6+86293ac">37587549</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad461>10.1093/eurheartj/ehad461</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37587549</guid><pubDate> Wed, 16 Aug 2023 06:00:00 -0400</pubDate><dc:creator>伊夫·杜德肯</dc:creator><dc:creator>喜森英里</dc:creator><dc:creator>阿莉西娅·维娜</dc:creator><dc:date>2023-08-16</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>在儿科人群中，罗斯手术相对于其他瓣膜替代术的优越性：这仅仅是开始！</dc:title><dc:identifier>下午：37587549</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad461</dc:identifier></item><item><title>匹伐他汀可减少 HIV 感染患者的心血管事件</title><link/>https://pubmed.ncbi.nlm.nih.gov/37587223/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230817021022&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol.2023 年 8 月 16 日。doi：10.1038/s41569-023-00920-z。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37587223/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817021022&v=2.17.9.post6+86293ac">37587223</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00920-z>10.1038/s41569-023-00920-z</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37587223</guid><pubDate> Wed, 16 Aug 2023 06:00:00 -0400</pubDate><dc:creator>卡琳娜·黄</dc:creator><dc:date>2023-08-16</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>匹伐他汀可减少 HIV 感染患者的心血管事件</dc:title><dc:identifier>下午：37587223</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00920-z</dc:identifier></item><item><title>心脏亚结构的辐射剂量与乳腺癌放射治疗后主要缺血事件的关系</title><link/>https://pubmed.ncbi.nlm.nih.gov/37585426/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230817021022&amp;v=2.17.9.post6+86293ac<description>结论：现代放疗时代存在重大缺血事件的风险，LV V25≥4%似乎是预测重大缺血事件的最佳参数，在预测放疗方面优于MHD，但仍需进一步验证研究。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 16 日：ehad462。doi：10.1093/eurheartj/ehad462。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：左侧乳腺癌患者在放疗后接受较高的平均心脏剂量（MHD），随之而来的是缺血性心脏病的风险。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法和结果：本研究回顾性评价了2158名接受辅助放疗的乳腺癌女性，主要终点是主要缺血事件，计算了每个描绘的心脏亚结构的剂量-体积参数。通过 Cox 回归分析 MHD 和主要缺血事件。通过比较每个模型的性能指标，在多变量模型中探索心脏亚结构中的最佳剂量体积预测因子。中位随访时间为 7.9 年（四分位数间距 5.6-10.8 年） ，89名患者出现严重缺血事件。主要缺血事件的累积发生率在左侧疾病中显着更高（P = 0.044）。总体而言，MHD每Gy使主要缺血事件的风险增加6.2%（风险比1.062， 95% 置信区间 1.01-1.12；P = 0.012)。包含接受 25 Gy (LV V25) 的左心室体积、切点为 4% 的模型在左侧呈现出最佳的拟合度和辨别性能。单侧乳腺癌。年龄、慢性肾病和高脂血症也是重要的危险因素。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：现代放疗时代存在重大缺血事件的风险，LV V25≥4%似乎是预测重大缺血事件的最佳参数，在预测放疗方面优于MHD，但仍需进一步验证研究。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37585426/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817021022&v=2.17.9.post6+86293ac">37585426</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad462>10.1093/eurheartj/ehad462</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37585426</guid><pubDate> Wed, 16 Aug 2023 06:00:00 -0400</pubDate><dc:creator>赖子钰</dc:creator><dc:creator>胡玉文</dc:creator><dc:creator>王体豪</dc:creator><dc:creator>陈瑞品</dc:creator><dc:creator>萧正英</dc:creator><dc:creator>黄品仪</dc:creator><dc:creator>易春丽</dc:creator><dc:creator>曾令明</dc:creator><dc:creator>黄妮可</dc:creator><dc:creator>刘家仁</dc:creator><dc:date>2023-08-16</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>心脏亚结构的辐射剂量与乳腺癌放射治疗后主要缺血事件的关系</dc:title><dc:identifier>下午：37585426</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad462</dc:identifier></item><item><title>女性心血管疾病诊断和治疗的差异：欧洲心脏病学会患者论坛呼吁采取联合行动</title><link/>https://pubmed.ncbi.nlm.nih.gov/37585369/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230817021022&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 16 日：ehad480。doi：10.1093/eurheartj/ehad480。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37585369/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817021022&v=2.17.9.post6+86293ac">37585369</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad480>10.1093/eurheartj/ehad480</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37585369</guid><pubDate> Wed, 16 Aug 2023 06:00:00 -0400</pubDate><dc:creator>玛丽·加尔布雷斯</dc:creator><dc:creator>——英加·德罗萨特</dc:creator><dc:date>2023-08-16</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>女性心血管疾病诊断和治疗的差异：欧洲心脏病学会患者论坛呼吁采取联合行动</dc:title><dc:identifier>下午：37585369</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad480</dc:identifier></item><item><title>芭芭拉·卡萨迪 (Barbara Casadei) 因心房颤动杰出研究而获奖</title><link/>https://pubmed.ncbi.nlm.nih.gov/37585368/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230817021022&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 16 日：ehad495。doi：10.1093/eurheartj/ehad495。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37585368/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817021022&v=2.17.9.post6+86293ac">37585368</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad495>10.1093/eurheartj/ehad495</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37585368</guid><pubDate> Wed, 16 Aug 2023 06:00:00 -0400</pubDate><dc:creator>朱迪思·奥兹坎</dc:creator><dc:date>2023-08-16</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>芭芭拉·卡萨迪 (Barbara Casadei) 因心房颤动杰出研究而获奖</dc:title><dc:identifier>下午：37585368</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad495</dc:identifier></item><item><title>衷心的震动：赋予社区减轻地震和其他自然灾害影响的能力</title><link/>https://pubmed.ncbi.nlm.nih.gov/37585357/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230817021022&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 16 日：ehad497。doi：10.1093/eurheartj/ehad497。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37585357/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817021022&v=2.17.9.post6+86293ac">37585357</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad497>10.1093/eurheartj/ehad497</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37585357</guid><pubDate> Wed, 16 Aug 2023 06:00:00 -0400</pubDate><dc:creator>图巴·凯马洛鲁·奥兹</dc:creator><dc:creator>扎伊纳布·阿提亚·达希尔</dc:creator><dc:date>2023-08-16</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>衷心的震动：赋予社区减轻地震和其他自然灾害影响的能力</dc:title><dc:identifier>下午：37585357</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad497</dc:identifier></item><item><title>低收入和中低收入国家心脏骤停治疗面临的挑战</title><link/>https://pubmed.ncbi.nlm.nih.gov/37585355/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230817021022&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 16 日：ehad492。doi：10.1093/eurheartj/ehad492。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37585355/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817021022&v=2.17.9.post6+86293ac">37585355</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad492>10.1093/eurheartj/ehad492</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37585355</guid><pubDate> Wed, 16 Aug 2023 06:00:00 -0400</pubDate><dc:creator>米莉卡·阿列克西奇</dc:creator><dc:date>2023-08-16</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>低收入和中低收入国家心脏骤停治疗面临的挑战</dc:title><dc:identifier>下午：37585355</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad492</dc:identifier></item><item><title> Liv Hatle 教授 1936-2023，超声心脏病学先驱和元老</title><link/>https://pubmed.ncbi.nlm.nih.gov/37585354/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230817021022&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 16 日：ehad478。doi：10.1093/eurheartj/ehad478。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37585354/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817021022&v=2.17.9.post6+86293ac">37585354</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad478>10.1093/eurheartj/ehad478</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37585354</guid><pubDate> Wed, 16 Aug 2023 06:00:00 -0400</pubDate><dc:creator>乔治·R·萨瑟兰</dc:creator><dc:creator>巴特·比南斯</dc:creator><dc:creator>艾伦·弗雷泽</dc:creator><dc:date>2023-08-16</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>Liv Hatle 教授 1936-2023，超声心脏病学先驱和元老</dc:title><dc:identifier>下午：37585354</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad478</dc:identifier></item><item><title>三磷酸腺苷柠檬酸裂解酶和脂肪酸合成抑制：叙述回顾</title><link/>https://pubmed.ncbi.nlm.nih.gov/37585218/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230817021022&amp;v=2.17.9.post6+86293ac<description>结论和相关性：对于需要进一步降低 LDL-C 的高危患者，尤其是有他汀类药物不耐受史的患者，使用 bempedoic 酸抑制 ACLY 已被确定为一种安全有效的治疗方法。在使用 bempedoic 酸治疗心血管事件时，与在他汀类药物不耐受且 LDL-C 水平为 100 mg/dL 或更高的高危个体中，其 LDL-C 降低。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 年 8 月 16 日。doi：10.1001/jamacardio.2023.2402。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：三磷酸腺苷柠檬酸裂解酶 (ACLY) 是葡萄糖代谢、胆固醇和脂肪酸合成以及炎症级联反应的关键调节酶。-C)、非高密度脂蛋白胆固醇和载脂蛋白 B。ACLY 抑制的其他作用包括抗肿瘤生长；减少甘油三酯和促炎分子，如高敏 C 反应蛋白；减少胰岛素抵抗；减少肝脏脂肪生成；以及减轻体重。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">观察：虽然已经鉴定出多种 ALY 抑制剂，但大多数临床数据都集中在 bempedoic Acid。通过 Bempedoic Acid 降低胆固醇，ACL 抑制方案 (CLEAR) 计划是一系列 3 期临床试验，评估其对脂质参数和安全性，导致美国食品和药物管理局于 2020 年批准。CLEAR Outcomes 是一项 3 期、双盲、随机、安慰剂对照试验，受试者为有他汀类药物不耐受史、血清 LDL-C 水平为 100 mg 的个体/dL 或更高，并且有心血管疾病史或有心血管疾病高风险。Bempedoic 酸适度降低主要 4 向心血管复合终点以及心肌梗死和冠状动脉血运重建的各个组成部分，但不会减少中风、心血管死亡或全因死亡率。使用 bempedoic 酸后痛风和胆石症的发生率较高，并且还观察到血清肌酐、尿酸和肝酶水平略有增加。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：对于需要进一步降低 LDL-C 的高危患者，尤其是有他汀类药物不耐受史的患者，使用 bempedoic 酸抑制 ACLY 已被确定为一种安全有效的治疗方法。在使用 bempedoic 酸治疗心血管事件时，与对于他汀类药物不耐受且 LDL-C 水平为 100 mg/dL 或更高的高危个体，其 LDL-C 降低。ALY 抑制剂可治疗癌症、高甘油三酯血症、慢性炎症、2 型糖尿病、脂肪肝、肥胖等疾病，和代谢综合征。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37585218/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817021022&v=2.17.9.post6+86293ac">37585218</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.2402>10.1001/jamacardio.2023.2402</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37585218</guid><pubDate> Wed, 16 Aug 2023 06:00:00 -0400</pubDate><dc:creator>弗雷迪·杜阿尔特·刘</dc:creator><dc:creator>罗伯特·朱利亚诺</dc:creator><dc:date>2023-08-16</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>三磷酸腺苷柠檬酸裂解酶和脂肪酸合成抑制：叙述回顾</dc:title><dc:identifier>下午：37585218</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.2402</dc:identifier></item><item><title>当代美国健康队列所有人研究计划中种族和民族的代表性</title><link/>https://pubmed.ncbi.nlm.nih.gov/37585212/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230817021022&amp;v=2.17.9.post6+86293ac<description>结论和相关性：正在进行的 AoU 的招募趋势显示，一些具有地理趋势的主要种族群体的代表性相对提高。这些发现强调需要进一步定制和扩大针对不同人群的招募和参与计划。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 年 8 月 16 日。doi：10.1001/jamacardio.2023.2411。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：为了解决生物医学研究中的系统性差异，我们创建了“我们所有人 (AoU) 研究计划”，旨在确定美国健康结果的根本原因和后果。然而，AoU 的种族和民族多样性程度尚不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目标：量化不断增加的 AoU 全国健康队列中关键种族和族裔群体的代表性，并与他们在美国的实际代表性进行比较。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、设置和参与者：这项队列研究将 2017 年 5 月至 2022 年 6 月针对 18 岁及以上个人的 AoU 计划与美国人口普查局收集的 2020 年十年一次调查 (DEC) 进行了比较。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">暴露：非西班牙裔亚洲人、非西班牙裔黑人或非裔美国人、西班牙裔或拉丁裔、非西班牙裔白人以及 AoU 中未分类或多个种族的代表性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要成果和措施：相对于 DEC，全国和州一级 AoU 计划中每个种族群体代表性不足或代表性过高的程度。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：迄今为止，在 AoU 中的 358 705 名美国成年人中，个人被确定为以下种族和民族类别：12 710 名非西班牙裔亚裔 (3.5%)、73 348 名非西班牙裔黑人或非裔美国人 (20.5%)、58 名488 名西班牙裔或拉丁裔 (16.3%)、205 457 名非西班牙裔白人 (57.3%) 和 8702 名未分类或报告多个类别的人 (2.4%)。在 355 413 名拥有出生性别和年龄数据的参与者中，218 981 名 (61.6%) ）为女性，平均 (SD) 年龄为 53.1 (17.0) 岁，136 037 (38.28%) 为男性，平均 (SD) 年龄为 56.7 (17.0) 岁，395 人报告非二元性别 (0.1%)与美国相比，非西班牙裔黑人或非裔美国人在 AoU 中的比例高出 8.73%（AoU，20.5% [358 705 人中的 73 348 人] vs. DEC，11.7% [258 343 281 人中的 30 266 080 人]）按相对规模计算，为 1.94 倍。非西班牙裔白人在 AoU 中的参与度最高，在所有地区总体上都占据主导地位，但在数量上代表性不足，绝对差异为 -3.54%（95% CI，-3.70 至 -3.38） . AoU 中未分类或多种族群体（2.4% [8702 of 358 705]）相对于 DEC（4.6% [11 922] 096 of 258 343 281]）的可能性是 0.43 倍，绝对差异为 - 2.19%（95% CI，-2.24 至 -2.14）。）在大多数州尤为突出。被认定为西班牙裔或拉丁裔的个人名义上代表性不足，为 -0.46%（95% CI，-0.58 至 -0.34）（AoU，16.3% [ 58 488 / 358 705] vs DEC，16.8% [43 322 792 / 258 343 281]）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：正在进行的 AoU 的招募趋势显示，一些具有地理趋势的主要种族群体的代表性相对提高。这些发现强调需要进一步定制和扩大针对不同人群的招募和参与计划。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37585212/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817021022&v=2.17.9.post6+86293ac">37585212</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.2411>10.1001/jamacardio.2023.2411</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37585212</guid><pubDate> Wed, 16 Aug 2023 06:00:00 -0400</pubDate><dc:creator>尼娜·凯瑟瑞桑</dc:creator><dc:creator>苏美杰玛·曹</dc:creator><dc:creator>罗米特·巴塔查亚 (Romit Bhattacharya)</dc:creator><dc:creator>布张</dc:creator><dc:creator>——惠特尼·霍恩斯比</dc:creator><dc:creator>普拉迪普·纳塔拉詹</dc:creator><dc:date>2023-08-16</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>当代美国健康队列所有人研究计划中种族和民族的代表性</dc:title><dc:identifier>下午：37585212</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.2411</dc:identifier></item><item><title>氟喹诺酮类药物的使用与主动脉瘤或主动脉夹层住院之间的关系</title><link/>https://pubmed.ncbi.nlm.nih.gov/37585175/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230817021022&amp;v=2.17.9.post6+86293ac<description>结论和相关性：本研究的结果表明，氟喹诺酮类药物与主动脉瘤或夹层关联的估计可能会受到混杂因素的影响。当考虑到这种混杂因素时，没有明显的关联性，这为氟喹诺酮类药物在主动脉瘤方面的安全性提供了保证。动脉瘤或夹层。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 年 8 月 16 日。doi：10.1001/jamacardio.2023.2418。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：在非介入性研究中，氟喹诺酮类药物的使用与主动脉瘤或夹层的住院率增加有关，但观察到的这种关联的原因尚不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：使用多项研究设计和多个数据库来确定氟喹诺酮类药物的使用与主动脉瘤或夹层之间的关联，以提高研究结果的稳健性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、设置和参与者：在英国初级保健记录的 2 个数据库中分别进行队列和病例交叉研究。临床实践研究数据链 Aurum 和 GOLD 初级保健记录与入院数据相关联。全身服用氟喹诺酮或头孢菌素处方的成人队列研究纳入1997年4月至2019年12月期间因主动脉瘤或夹层住院的成人纳入病例交叉研究，符合病例交叉研究纳入标准的个体以1:3匹配至对照个人的年龄、性别、索引日期和临床实践，以根据处方日历趋势进行调整。数据分析时间为 2022 年 1 月至 7 月。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">暴露：全身性氟喹诺酮类药物或对照抗生素。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和测量：在队列研究中，使用治疗加权 Cox 回归的稳定逆概率来估计氟喹诺酮类药物处方与主动脉瘤或夹层住院之间的关联的风险比 (HR)。使用条件逻辑回归模型对全身使用氟喹诺酮类药物与主动脉瘤或夹层住院之间的关联进行病例交叉研究。使用固定效应荟萃分析对跨数据库的估计值进行汇总。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在队列研究中，我们确定了 Aurum 的 3 134 121 名成年人（平均 [SD] 年龄，52.5 [20.3] 岁；女性 1 969 257 [62.8%]）和 GOLD 的 452 086 名成年人（平均 [SD] 年龄，53.9 岁） [20.2] 岁；286 502 [63.4%] 女性）服用氟喹诺酮类药物或头孢菌素。-1.44；P &lt; .001），但在调整潜在混杂因素后，这种关联消失了（合并调整后 HR，1.03；95% CI，0.91） –1.17；P = .65）。Aurum 因主动脉瘤或夹层住院的个体（平均 [SD] 年龄，75.5 [10.9]；23 551 名女性 [27.8%]）和 GOLD 10 357 名（平均 [SD] 年龄， 75.6 [10.5]；2809 [27.1% ] 女性）。95% CI，0.75-1.06；对比阿莫西拉，0.98；95% CI，0.82-1.18）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：本研究的结果表明，氟喹诺酮类药物与主动脉瘤或夹层关联的估计可能会受到混杂因素的影响。当考虑到这种混杂因素时，没有明显的关联性，这为氟喹诺酮类药物在主动脉瘤方面的安全性提供了保证。动脉瘤或夹层。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37585175/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817021022&v=2.17.9.post6+86293ac">37585175</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.2418>10.1001/jamacardio.2023.2418</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37585175</guid><pubDate> Wed, 16 Aug 2023 06:00:00 -0400</pubDate><dc:creator>杰里米·P·布朗</dc:creator><dc:creator>凯文·温</dc:creator><dc:creator>克莱门斯·莱拉特</dc:creator><dc:creator>斯蒂芬·埃文斯</dc:creator><dc:creator>凯瑟琳·E·曼斯菲尔德</dc:creator><dc:creator>天使王YS</dc:creator><dc:creator>利亚姆·斯密斯</dc:creator><dc:creator>——尼古拉斯·W·加尔威</dc:creator><dc:creator>伊恩·J·道格拉斯</dc:creator><dc:date>2023-08-16</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>氟喹诺酮类药物的使用与主动脉瘤或主动脉夹层住院之间的关系</dc:title><dc:identifier>下午：37585175</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.2418</dc:identifier></item><item><title>心脏骤停昏迷成年幸存者的温度管理：美国心脏协会的科学建议</title><link/>https://pubmed.ncbi.nlm.nih.gov/37584195/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230817021022&amp;v=2.17.9.post6+86293ac<description>自 2002 年的初步试验发现轻度治疗性低温可改善神经系统结果以来，有针对性的温度管理一直是心脏骤停后护理恢复自主循环后仍无反应的患者的基石。根据一项大型试验，建议的温度范围在 2015 年扩大了发现 33°C 治疗的结果并不比 36°C 更好。2021 年，发表了另一项大型试验，其中结果...... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 8 月 16 日。doi：10.1161/CIR.0000000000001164。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">自 2002 年的初步试验发现轻度治疗性低温可改善神经系统结果以来，有针对性的温度管理一直是心脏骤停后护理恢复自主循环后仍无反应的患者的基石。根据一项大型试验，建议的温度范围在 2015 年扩大了发现 33°C 治疗的结果并不比 36°C 更好。2021 年，发表了另一项大型试验，其中温度控制在 33°C 的结果并不比采用严格常温策略治疗的患者更好根据这些新数据，国际复苏联络委员会和其他组织改变了心脏骤停后体温管理的治疗建议。美国心脏协会关于这一主题的新指南将在 2023 年重点更新中推出。虽然这一重点更新即将发布，但美国心脏协会的紧急心血管护理委员会召集了一个写作小组，根据最近的其他证据审查 TTM2 试验（院外心脏骤停后体温过低与正常体温），并就以下问题提出意见：该试验如何影响临床实践。本科学咨询的依据是对 TTM2 试验的回顾、对最近其他有影响力的研究的考虑以及心脏病学、重症监护、急诊医学和神经病学领域的心脏骤停专家之间的讨论。本咨询声明不会取代现行指南，而是旨在提供有关新颖文献的专家意见，这些意见将纳入未来的指南，并为重新评估当前临床实践提供机会。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37584195/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817021022&v=2.17.9.post6+86293ac">37584195</a> | DOI： <a href=https://doi.org/10.1161/CIR.0000000000001164>10.1161/CIR.0000000000001164</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37584195</guid><pubDate> Wed, 16 Aug 2023 06:00:00 -0400</pubDate><dc:creator>莎拉·M·帕尔曼</dc:creator><dc:creator>——贾森·A·巴托斯</dc:creator><dc:creator>玛丽娜德尔里奥斯</dc:creator><dc:creator>——迈克尔·W·唐尼诺</dc:creator><dc:creator>凯伦·G·赫希</dc:creator><dc:creator>雅各布·C·詹策尔</dc:creator><dc:creator>彼得·J·库登丘克</dc:creator><dc:creator>——迈克尔·库尔兹</dc:creator><dc:creator>卡罗莱纳·B·马西尔</dc:creator><dc:creator>维努·梅农</dc:creator><dc:creator>阿什什·R·潘查尔</dc:creator><dc:creator>乔恩·C·里滕伯格</dc:creator><dc:creator>凯瑟琳·伯格</dc:creator><dc:creator>美国心脏协会心血管急救委员会、心血管手术和麻醉委员会、临床心脏病学委员会、心血管和中风护理委员会、周围血管疾病委员会、心血管和中风护理委员会、</dc:creator><dc:date> 2023-08-16</dc:date><dc:source>循环</dc:source><dc:title>心脏骤停昏迷成年幸存者的温度管理：美国心脏协会的科学建议</dc:title><dc:identifier>下午：37584195</dc:identifier><dc:identifier>号码：10.1161/CIR.0000000000001164</dc:identifier></item><item><title>克拉、净度、颜色和切工：对钻石试验进行分级</title><link/>https://pubmed.ncbi.nlm.nih.gov/37583291/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230817021022&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 16 日：ehad469。doi：10.1093/eurheartj/ehad469。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37583291/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817021022&v=2.17.9.post6+86293ac">37583291</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad469>10.1093/eurheartj/ehad469</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37583291</guid><pubDate> Wed, 16 Aug 2023 06:00:00 -0400</pubDate><dc:creator>贾维德·巴特勒</dc:creator><dc:creator>杰弗里·巴登</dc:creator><dc:creator>伯特伦·皮特</dc:creator><dc:creator>斯特凡·安克</dc:creator><dc:date>2023-08-16</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>克拉、净度、颜色和切工：对钻石试验进行分级</dc:title><dc:identifier>下午：37583291</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad469</dc:identifier></item><item><title> Detailed safety analysis of DIAMOND trial: &#39;primum non nocere&#39;?</title><link/> https://pubmed.ncbi.nlm.nih.gov/37583279/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230817021022&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 16:ehad473. doi: 10.1093/eurheartj/ehad473. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37583279/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817021022&v=2.17.9.post6+86293ac">37583279</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad473>10.1093/eurheartj/ehad473</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37583279</guid><pubDate> Wed, 16 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Rui Baptista</dc:creator><dc:creator> Sara Gonçalves</dc:creator><dc:creator> Ricardo Fontes-Carvalho</dc:creator><dc:date> 2023-08-16</dc:date><dc:source> European heart journal</dc:source><dc:title> Detailed safety analysis of DIAMOND trial: &#39;primum non nocere&#39;?</dc:title><dc:identifier> pmid:37583279</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad473</dc:identifier></item><item><title> Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation</title><link/> https://pubmed.ncbi.nlm.nih.gov/37582358/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230817021022&amp;v=2.17.9.post6+86293ac<description> Post-translational modifications (PTMs) play key roles in regulating cell signaling and physiology in both normal and cancer cells. Advances in mass spectrometry enable high-throughput, accurate, and sensitive measurement of PTM levels to better understand their role, prevalence, and crosstalk. Here, we analyze the largest collection of proteogenomics data from 1,110 patients with PTM profiles across 11 cancer types (10 from the National Cancer Institute&#39;s Clinical Proteomic Tumor Analysis... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Aug 9:S0092-8674(23)00781-X. doi: 10.1016/j.cell.2023.07.013. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Post-translational modifications (PTMs) play key roles in regulating cell signaling and physiology in both normal and cancer cells. Advances in mass spectrometry enable high-throughput, accurate, and sensitive measurement of PTM levels to better understand their role, prevalence, and crosstalk. Here, we analyze the largest collection of proteogenomics data from 1,110 patients with PTM profiles across 11 cancer types (10 from the National Cancer Institute&#39;s Clinical Proteomic Tumor Analysis Consortium [CPTAC]). Our study reveals pan-cancer patterns of changes in protein acetylation and phosphorylation involved in hallmark cancer processes. These patterns revealed subsets of tumors, from different cancer types, including those with dysregulated DNA repair driven by phosphorylation, altered metabolic regulation associated with immune response driven by acetylation, affected kinase specificity by crosstalk between acetylation and phosphorylation, and modified histone regulation. Overall, this resource highlights the rich biology governed by PTMs and exposes potential new therapeutic avenues.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37582358/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817021022&v=2.17.9.post6+86293ac">37582358</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.07.013>10.1016/j.cell.2023.07.013</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37582358</guid><pubDate> Tue, 15 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Yifat Geffen</dc:creator><dc:creator> Shankara Anand</dc:creator><dc:creator> Yo Akiyama</dc:creator><dc:creator> Tomer M Yaron</dc:creator><dc:creator> Yizhe Song</dc:creator><dc:creator> Jared L Johnson</dc:creator><dc:creator> Akshay Govindan</dc:creator><dc:creator> Özgün Babur</dc:creator><dc:creator> Yize Li</dc:creator><dc:creator> Emily Huntsman</dc:creator><dc:creator> Liang-Bo Wang</dc:creator><dc:creator> Chet Birger</dc:creator><dc:creator> David I Heiman</dc:creator><dc:creator> Qing Zhang</dc:creator><dc:creator> Mendy Miller</dc:creator><dc:creator> Yosef E Maruvka</dc:creator><dc:creator> Nicholas J Haradhvala</dc:creator><dc:creator> Anna Calinawan</dc:creator><dc:creator> Saveliy Belkin</dc:creator><dc:creator> Alexander Kerelsky</dc:creator><dc:creator> Karl R Clauser</dc:creator><dc:creator> Karsten Krug</dc:creator><dc:creator> Shankha Satpathy</dc:creator><dc:creator> Samuel H Payne</dc:creator><dc:creator> DR Mani</dc:creator><dc:creator> Michael A Gillette</dc:creator><dc:creator> Saravana M Dhanasekaran</dc:creator><dc:creator> Mathangi Thiagarajan</dc:creator><dc:creator> Mehdi Mesri</dc:creator><dc:creator> Henry Rodriguez</dc:creator><dc:creator> Ana I Robles</dc:creator><dc:creator> Steven A Carr</dc:creator><dc:creator> Alexander J Lazar</dc:creator><dc:creator> François Aguet</dc:creator><dc:creator> Lewis C Cantley</dc:creator><dc:creator> Li Ding</dc:creator><dc:creator> Gad Getz</dc:creator><dc:creator> Clinical Proteomic Tumor Analysis Consortium</dc:creator><dc:date> 2023-08-15</dc:date><dc:source> Cell</dc:source><dc:title> Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation</dc:title><dc:identifier> pmid:37582358</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.07.013</dc:identifier></item><item><title> Pan-cancer proteogenomics connects oncogenic drivers to functional states</title><link/> https://pubmed.ncbi.nlm.nih.gov/37582357/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230817021022&amp;v=2.17.9.post6+86293ac<description> Cancer driver events refer to key genetic aberrations that drive oncogenesis; however, their exact molecular mechanisms remain insufficiently understood. Here, our multi-omics pan-cancer analysis uncovers insights into the impacts of cancer drivers by identifying their significant cis-effects and distal trans-effects quantified at the RNA, protein, and phosphoprotein levels. Salient observations include the association of point mutations and copy-number alterations with the rewiring of protein... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Aug 14:S0092-8674(23)00780-8. doi: 10.1016/j.cell.2023.07.014. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Cancer driver events refer to key genetic aberrations that drive oncogenesis; however, their exact molecular mechanisms remain insufficiently understood. Here, our multi-omics pan-cancer analysis uncovers insights into the impacts of cancer drivers by identifying their significant cis-effects and distal trans-effects quantified at the RNA, protein, and phosphoprotein levels. Salient observations include the association of point mutations and copy-number alterations with the rewiring of protein interaction networks, and notably, most cancer genes converge toward similar molecular states denoted by sequence-based kinase activity profiles. A correlation between predicted neoantigen burden and measured T cell infiltration suggests potential vulnerabilities for immunotherapies. Patterns of cancer hallmarks vary by polygenic protein abundance ranging from uniform to heterogeneous. Overall, our work demonstrates the value of comprehensive proteogenomics in understanding the functional states of oncogenic drivers and their links to cancer development, surpassing the limitations of studying individual cancer types.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37582357/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817021022&v=2.17.9.post6+86293ac">37582357</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.07.014>10.1016/j.cell.2023.07.014</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37582357</guid><pubDate> Tue, 15 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Yize Li</dc:creator><dc:creator> Eduard Porta-Pardo</dc:creator><dc:creator> Collin Tokheim</dc:creator><dc:creator> Matthew H Bailey</dc:creator><dc:creator> Tomer M Yaron</dc:creator><dc:creator> Vasileios Stathias</dc:creator><dc:creator> Yifat Geffen</dc:creator><dc:creator> Kathleen J Imbach</dc:creator><dc:creator> Song Cao</dc:creator><dc:creator> Shankara Anand</dc:creator><dc:creator> Yo Akiyama</dc:creator><dc:creator> Wenke Liu</dc:creator><dc:creator> Matthew A Wyczalkowski</dc:creator><dc:creator> Yizhe Song</dc:creator><dc:creator> Erik P Storrs</dc:creator><dc:creator> Michael C Wendl</dc:creator><dc:creator> Wubing Zhang</dc:creator><dc:creator> Mustafa Sibai</dc:creator><dc:creator> Victoria Ruiz-Serra</dc:creator><dc:creator> Wen-Wei Liang</dc:creator><dc:creator> Nadezhda V Terekhanova</dc:creator><dc:creator> Fernanda Martins Rodrigues</dc:creator><dc:creator> Karl R Clauser</dc:creator><dc:creator> David I Heiman</dc:creator><dc:creator> Qing Zhang</dc:creator><dc:creator> Francois Aguet</dc:creator><dc:creator> Anna P Calinawan</dc:creator><dc:creator> Saravana M Dhanasekaran</dc:creator><dc:creator> Chet Birger</dc:creator><dc:creator> Shankha Satpathy</dc:creator><dc:creator> Daniel Cui Zhou</dc:creator><dc:creator> Liang-Bo Wang</dc:creator><dc:creator> Jessika Baral</dc:creator><dc:creator> Jared L Johnson</dc:creator><dc:creator> Emily M Huntsman</dc:creator><dc:creator> Pietro Pugliese</dc:creator><dc:creator> Antonio Colaprico</dc:creator><dc:creator> Antonio Iavarone</dc:creator><dc:creator> Milan G Chheda</dc:creator><dc:creator> Christopher J Ricketts</dc:creator><dc:creator> David Fenyö</dc:creator><dc:creator> Samuel H Payne</dc:creator><dc:creator> Henry Rodriguez</dc:creator><dc:creator> Ana I Robles</dc:creator><dc:creator> Michael A Gillette</dc:creator><dc:creator> Chandan Kumar-Sinha</dc:creator><dc:creator> Alexander J Lazar</dc:creator><dc:creator> Lewis C Cantley</dc:creator><dc:creator> Gad Getz</dc:creator><dc:creator> Li Ding</dc:creator><dc:creator> Clinical Proteomic Tumor Analysis Consortium</dc:creator><dc:date> 2023-08-15</dc:date><dc:source> Cell</dc:source><dc:title> Pan-cancer proteogenomics connects oncogenic drivers to functional states</dc:title><dc:identifier> pmid:37582357</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.07.014</dc:identifier></item><item><title> Heart disease causes sleep disturbances via neuroimmune mechanisms</title><link/> https://pubmed.ncbi.nlm.nih.gov/37580430/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230817021022&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol. 2023 Aug 14. doi: 10.1038/s41569-023-00921-y. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37580430/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817021022&v=2.17.9.post6+86293ac">37580430</a> | DOI: <a href=https://doi.org/10.1038/s41569-023-00921-y>10.1038/s41569-023-00921-y</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37580430</guid><pubDate> Mon, 14 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Irene Fernández-Ruiz</dc:creator><dc:date> 2023-08-14</dc:date><dc:source> Nature reviews. Cardiology</dc:source><dc:title> Heart disease causes sleep disturbances via neuroimmune mechanisms</dc:title><dc:identifier> pmid:37580430</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00921-y</dc:identifier></item><item><title> Animal models to study cardiac regeneration</title><link/> https://pubmed.ncbi.nlm.nih.gov/37580429/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230817021022&amp;v=2.17.9.post6+86293ac<description> Permanent fibrosis and chronic deterioration of heart function in patients after myocardial infarction present a major health-care burden worldwide. In contrast to the restricted potential for cellular and functional regeneration of the adult mammalian heart, a robust capacity for cardiac regeneration is seen during the neonatal period in mammals as well as in the adults of many fish and amphibian species. However, we lack a complete understanding as to why cardiac regeneration takes place more... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol. 2023 Aug 14. doi: 10.1038/s41569-023-00914-x. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Permanent fibrosis and chronic deterioration of heart function in patients after myocardial infarction present a major health-care burden worldwide. In contrast to the restricted potential for cellular and functional regeneration of the adult mammalian heart, a robust capacity for cardiac regeneration is seen during the neonatal period in mammals as well as in the adults of many fish and amphibian species. However, we lack a complete understanding as to why cardiac regeneration takes place more efficiently in some species than in others. The capacity of the heart to regenerate after injury is controlled by a complex network of cellular and molecular mechanisms that form a regulatory landscape, either permitting or restricting regeneration. In this Review, we provide an overview of the diverse array of vertebrates that have been studied for their cardiac regenerative potential and discuss differential heart regeneration outcomes in closely related species. Additionally, we summarize current knowledge about the core mechanisms that regulate cardiac regeneration across vertebrate species.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37580429/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817021022&v=2.17.9.post6+86293ac">37580429</a> | DOI: <a href=https://doi.org/10.1038/s41569-023-00914-x>10.1038/s41569-023-00914-x</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37580429</guid><pubDate> Mon, 14 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Michael Weinberger</dc:creator><dc:creator> Paul R Riley</dc:creator><dc:date> 2023-08-14</dc:date><dc:source> Nature reviews. Cardiology</dc:source><dc:title> Animal models to study cardiac regeneration</dc:title><dc:identifier> pmid:37580429</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00914-x</dc:identifier></item></channel></rss>